Fetal Chromosomal Aneuploidy (T21, T18, T13) Test Kit (reversible termination sequencing)

Trisomy 21, trisomy 18 and trisomy 13 are the most common chromosomal aneuploidies in clinical practice. The corresponding diseases are trisomy 21 (also known as Down syndrome), trisomy 18 (also known as Edwards syndrome) and trisomy 13 (also known as Patau syndrome), with an incidence of about 1/700, 1/6000 and 1/10,000, respectively. Most of the patients had severe mental retardation and organ malformations. Prenatal screening and prenatal diagnosis are effective means to avoid the birth of children with genetic defects. Cell-free fetal DNA(cffDNA) exists in maternal peripheral blood. The content of cffDNA in maternal plasma has a certain relationship with gestational age, and fluctuates within a certain range. When the number of a chromosome in the fetus is abnormal, the proportion of cffDNA in that chromosome will exceed the normal range. By sequencing, we can calculate the proportion of DNA fragments in the plasma of each chromosome, and thus obtain information about the number of chromosomes. Based on the above principle, Geneture Fetal Chromosomal Aneuploidy (T21, T18, T13) Test Kit uses the next generation high-throughput sequencing platform to detect fetal cell-free DNA in peripheral blood plasma of pregnant women at 12+ 0~22 +6 gestational weeks, and complete the prenatal screening of fetal chromosomal aneuploidies including T21, T18 and T13.